Foresite Capital. (6/12/24). "Press Release: Foresite Capital Raises $900M to Invest in Healthcare and Life Science Startups at All Stages". San Francisco, CA.

	Organisation	Foresite Capital Fund VI
	Group	Foresite Capital (Group)
	Organisation 2	Xaira Therapeutics
	Product	Foresite Capital Fund VI
	Product 2	LIFE SCIENCES
	Index term	Foresite Capital–SEVERAL: investment, 202406 final closing of Fund VI with $900m in capital commitments
	Index term 2	Foresite Capital–VSC (US): public relations, 202406 service existent by VSC
	Person	Tananbaum, James (Jim) (Foresite Capital 201609 CEO + Managing Director + Co-Founder)
	Person 2	Tabbaa, Hadi (Foresite Capital 202406 Managing Director + Head of IR + Business Development)

Foresite Capital, a multi-stage healthcare and life sciences investment firm with more than $3.5 billion under management, announced today that it has closed its sixth fund with $900 million in capital commitments. With this new fund, Foresite Capital continues to invest in groundbreaking technologies, ranging from novel therapeutics to companies at the intersection of technology and biotechnology.

“Fund VI is deploying capital into what I believe is one of the best biotech investment environments of my career,” said Jim Tananbaum, founder and CEO of Foresite Capital. “Advances in biology, genomics and artificial intelligence continue to converge. Biotech innovation is predicting, preventing and treating disease more effectively than ever before. We believe these advances will lead to increasingly efficient investing at all stages.”

Fund VI is investing in innovative, growth-oriented companies in three main areas: precision therapeutics, life science infrastructure, and healthcare delivery, including Alumis, CG Oncology, Latigo, RayThera and Xaira Therapeutics.

Limited partners of Fund VI include a broad range of investors, among them university endowments, charitable foundations, medical institutions, pension funds, insurance companies, private banks and family offices worldwide.

“We’re grateful for the support we’ve received from both long-standing partners and new investors alike,” said Hadi Tabbaa, Managing Director and Head of Investor Relations and Business Development. “Their partnership with Foresite Capital enables our support of entrepreneurs who are addressing some of the most vexing aspects of our healthcare system and improving the lives of patients.”

Since its establishment in 2011, Foresite has adhered to a data and science-driven investment strategy, resulting in more than 47 IPOs, 28 mergers and acquisitions and the approval of 58 drugs by the FDA. Foresite’s team offers comprehensive support to its portfolio companies, leveraging expertise in company formation, therapeutics product development, and data science / machine learning to provide strategic guidance and technical assistance.

About Foresite Capital

Foresite Capital is a multi-stage healthcare and life sciences investment firm with more than $3.5 billion in assets under management. The firm aims to address areas of unmet medical need by funding promising healthcare and life sciences businesses at all stages of their life cycles. Founded in 2011, Foresite Capital is based in the San Francisco Bay Area, Los Angeles, and New York City. For more information, please visit www.foresitecapital.com.

Contacts

Kayla Abbassi
VSC for Foresite Capital
foresite@vsc.co

Record changed: 2024-06-21